Anal Fistula Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

An anal fistula (fistula-in-ano) is an abnormal tunnel connecting the inside of the anal canal — almost always originating at an infected anal gland in the intersphincteric groove at the dentate line — to an opening on the perianal skin. It is almost always the consequence of a prior perianal abscess: when an abscess forms in an anal gland and spontaneously drains (or is surgically drained), the residual infected track fails to heal, leaving a persistent fistulous communication. The lifetime incidence is approximately 1–2 per 10,000 population, with a 2:1 male predominance, and peak occurrence in the third to fifth decade.

Anal fistulae are classified by their anatomical relationship to the external anal sphincter using Parks' classification: (1) intersphincteric (45–70% of cases — track between internal and external sphincters), (2) transsphincteric (25–30% — track crosses through the external sphincter), (3) suprasphincteric (1–5%), and (4) extrasphincteric (<1%). 'Low' fistulae (intersphincteric and low transsphincteric — crossing less than one-third of the external sphincter) are amenable to simple fistulotomy with minimal incontinence risk. 'Complex' fistulae — high transsphincteric, suprasphincteric, extrasphincteric, anterior fistulae in women, fistulae in patients with pre-existing incontinence, Crohn's disease-associated fistulae, and horseshoe fistulae — require sphincter-preserving approaches to avoid devastating faecal incontinence.

Treatment selection is guided by the Parks classification, the extent of sphincter muscle involvement, the presence of Crohn's disease or other complicating factors, and the patient's pre-existing continence status. MRI (magnetic resonance imaging) of the pelvis with high-resolution pelvic floor sequences is the gold-standard investigation for complex fistulae, defining the anatomy of the primary track, secondary extensions, and relationship to sphincter muscles before surgical planning.

Cryptoglandular anal fistulae (arising from infected anal glands) account for 90–95% of all anal fistulae. The remaining 5–10% arise from secondary causes requiring specific treatment of the underlying condition alongside the fistula itself.

Crohn's disease-associated perianal fistulae: One of the most challenging presentations — occurring in 20–40% of patients with Crohn's disease, particularly those with colonic involvement. Crohn's perianal fistulae are often complex, multiple, and recurrent, requiring coordinated management by a colorectal surgeon and gastroenterologist. Anti-TNF biologic therapy (infliximab — ACCENT II trial, adalimumab — CHARM trial) achieves fistula closure in 35–50% of Crohn's perianal fistulae and is the cornerstone of systemic treatment. Surgical seton drainage provides infection control and patient comfort while medical therapy is optimised. NICE guidelines recommend combined biological + surgical approach for complex Crohn's perianal disease.

Rectovaginal fistulae: A communication between the rectum and vagina, causing passage of stool and gas per vagina. Causes include obstetric trauma (particularly 4th-degree perineal tears or failed repair), Crohn's disease, radiation (after pelvic radiotherapy for cervical or rectal cancer), and surgical complications. Requires specific repair techniques (gracilis muscle interposition, Martius graft, or local advancement flap) distinct from standard fistulotomy.

Recurrent anal fistulae after prior surgery: Recurrent fistulae after failed primary fistulotomy are common (10–30% after fistulotomy for complex fistulae) and require re-evaluation with MRI before planning revisional surgery. Repeat MRI identifies missed secondary tracks, residual primary tracks, and the remaining sphincter muscle available for sacrifice before re-intervention.

Horseshoe fistulae: A circumferential fistula extending from a posterior midline primary opening around both sides of the anus — a complex variant requiring staged or core-out surgical treatment.

All patients with a suspected anal fistula require examination under anaesthesia (EUA) as the definitive diagnostic and planning step — defining the primary opening, secondary opening(s), the track course, and degree of sphincter involvement by bidigital and probe examination. Rigid or flexible sigmoidoscopy/proctoscopy at EUA excludes anorectal pathology proximal to the dentate line. MRI pelvic fistula protocol (T2-weighted coronal and axial sequences of the anal canal and pelvic floor) provides the most accurate non-invasive assessment of fistula anatomy before complex surgery — particularly important for recurrent, Crohn's, or suprasphincteric fistulae.

Patients suitable for fistulotomy (lay-open technique): Those with simple low fistulae (intersphincteric or low transsphincteric) crossing less than one-third of the external sphincter, in patients without pre-existing sphincter weakness or incontinence, and where the fistula does not traverse critical sphincter muscle required for continence. The vast majority of simple cryptoglandular fistulae are managed with fistulotomy.

Patients requiring sphincter-preserving treatment: All patients with high transsphincteric (involving more than 30% of external sphincter), suprasphincteric, or extrasphincteric fistulae; anterior fistulae in women (short perineal body — high incontinence risk from fistulotomy); patients with pre-existing faecal incontinence (St Mark's Continence Score or Wexner score); elderly patients with weaker sphincter muscle; and all Crohn's disease fistulae. In these groups, sphincter division must be avoided to preserve continence.

Contraindications to immediate definitive surgery: Active uncontrolled sepsis — acute perianal abscess associated with the fistula must first be drained and controlled (with antibiotic therapy) before elective fistula surgery, which is planned 8–12 weeks after abscess resolution.

Fistulotomy (lay-open): The gold standard for simple low fistulae. The entire fistula track is laid open by incising the overlying skin and sphincter muscle, creating an open wound that heals by secondary intention (granulation) over 4–8 weeks. Cure rates are 92–97% for simple low fistulae. The key risk is faecal incontinence from division of sphincter muscle — risk is minimal for low fistulae but increases substantially as the proportion of external sphincter divided increases. After fistulotomy, regular wound packing (by the patient or district nurse) and sitz baths maintain wound hygiene during healing.

Seton drainage: A seton (a thread of nylon, silicone, or elastic) is passed through the fistula track and tied loosely (loose seton, 'draining seton') or tightly (cutting seton). A loose draining seton controls sepsis, maintains fistula track drainage, allows fibrosis of the track, and permits examination of residual sphincter before second-stage definitive treatment — used as a bridge to definitive sphincter-preserving surgery. A cutting seton slowly cuts through the sphincter muscle over weeks to months — largely abandoned at most centres as it provides poor continence outcomes compared to sphincter-preserving procedures.

LIFT procedure (Ligation of the Intersphincteric Fistula Track): A sphincter-preserving technique developed by Rojanasakul (2007). An incision is made in the intersphincteric groove; the fistula track is identified, ligated at both ends with absorbable sutures, and divided. Success rates of 50–80% across published series, with no risk to external sphincter continence. Particularly useful for transsphincteric fistulae where sphincter division would compromise continence.

Advancement flap repair: A flap of rectal mucosa and submucosa is raised and advanced to cover the internal opening of the fistula, obliterating the origin of the track. Success rates 50–75%. Risk of flap ischaemia and failure; requires dry, infection-free field. Suitable for high transsphincteric and rectovaginal fistulae.

Video-Assisted Anal Fistula Treatment (VAAFT): A newer minimally invasive technique using a fistuloscope (2.2 mm endoscope) to visualise the entire fistula track internally, cauterise the track mucosa under direct vision, and close the internal opening with a stapler or suture. Published success rates 68–87% at 12 months in European series. Advantages include minimal tissue destruction, sphincter preservation, and outpatient procedure. Not widely available in all centres.

Fibrin glue or fistula plug: Biologics (fibrin glue injection or collagen anal fistula plug) obliterate the fistula track. Low and variable success rates (14–55%) but essentially no risk of incontinence — used as a low-risk option when other procedures have failed or are contraindicated, or as a temporising measure in Crohn's patients.

Successful anal fistula treatment eliminates chronic discharge, pain, recurrent sepsis, and the significant impact on quality of life caused by persistent fistula. The primary benefit is resolution of symptoms and healing of the fistulous track without causing faecal incontinence.

Fistulotomy for simple low fistulae achieves cure rates of 92–97% with minimal incontinence risk — the most effective treatment for appropriate cases. After fistulotomy, wound healing is complete within 4–8 weeks; recurrence rates are low (3–8%) and almost always attributable to incomplete primary track identification at surgery or the presence of secondary tracks not appreciated at initial EUA.

For complex high fistulae, sphincter-preserving procedures avoid incontinence while achieving meaningful cure rates: LIFT procedure achieves 50–80% primary cure and allows repeat LIFT or alternative procedure for the 20–50% recurrence. Advancement flap repair achieves 50–75% primary cure. VAAFT, the most recently developed technique, shows promising results (68–87%) across European multicentre series with essentially no continence impairment.

For Crohn's perianal fistulae, combined biologic therapy (infliximab, adalimumab) and seton drainage achieves fistula closure in 35–50% at 54 weeks (ACCENT II long-term data). Complete combined surgical and medical management allows 60–70% of Crohn's perianal fistula patients to achieve sustained remission or significantly reduced fistula activity, substantially improving quality of life even when complete closure is not achieved. Faecal diversion with a temporary stoma is reserved as a last resort for refractory severe perianal Crohn's disease.

Faecal incontinence is the most important complication of anal fistula surgery and the primary reason why sphincter-preserving approaches are required for complex fistulae. Fistulotomy of high transsphincteric fistulae carries a risk of clinically significant incontinence (liquid stool, flatus) in 10–50% depending on the proportion of sphincter divided — this risk is why simple fistulotomy is inappropriate for high fistulae.

Recurrence is the main limitation of sphincter-preserving procedures: LIFT failure with fistula recurrence occurs in 20–50% of cases at 1 year; advancement flap failure in 25–50%; fibrin glue failure in 50–85%. Recurrence necessitates repeated surgical attempts, each carrying cumulative risk to sphincter function.

Post-operative sepsis and wound infection: Wound infections occur in 5–10% of procedures; perianal abscess formation at the site of the operation requires drainage. In VAAFT, equipment-related complications include equipment failure and incomplete track cauterisation causing persistent fistula.

Bleeding: Reactionary haemorrhage in the first 24 hours (1–2%) or secondary haemorrhage at 7–10 days (1–2%) during sloughing of the wound. Urinary retention requiring temporary catheterisation occurs in 5–10% of patients receiving spinal or epidural anaesthesia for perianal surgery.

Wound healing delay: The open wound from fistulotomy requires 4–8 weeks of twice-daily packing and sitz baths to heal — failure to maintain wound hygiene causes delayed healing and potentially re-infection. Patients must be counselled on wound care requirements before surgery. Bridge-to-healing sealants and silver-impregnated packing may accelerate healing in some centres.

Anal fistula surgery is performed as day surgery in the majority of cases, with overnight stay for complex multi-stage procedures or patients with significant comorbidities. Post-operative management:

Wound care after fistulotomy: Twice-daily sitz baths (warm water immersion for 10–15 minutes), followed by gentle wound packing with dressings, is the cornerstone of post-fistulotomy wound care. District nurse visits may be arranged for wound assessment and packing. The open wound must granulate from the base upward — overgrowth of wound edges must be prevented by daily packing. Complete healing takes 4–8 weeks for simple fistulotomy wounds.

Pain management: Post-operative anal pain is managed with regular paracetamol and NSAIDs; topical local anaesthetic gel (lidocaine 2%) applied before dressing changes provides additional comfort. Opioids should be minimised as they cause constipation, which increases post-operative pain and wound contamination risk. Stool softeners (macrogol, lactulose) are prescribed for the first 2–4 weeks to prevent constipation and hard stool passage across the healing wound.

Diet and activity: Normal diet is resumed immediately. Constipation should be avoided — high-fibre diet and adequate fluid intake are encouraged. Patients may return to sedentary work within 1–2 weeks of fistulotomy and within 2–4 weeks of more complex procedures. Heavy physical work and strenuous exercise are restricted for 4 weeks.

Outpatient follow-up: Review at 4–6 weeks assesses wound healing, confirms absence of residual fistula opening, and identifies early recurrence. For LIFT or advancement flap, examination at 3 months confirms primary healing. Continence assessment using a validated scoring tool (Wexner or St Mark's Continence Score) should be documented before and after any anal fistula surgery. Recurrence assessment with repeat EUA ± MRI at 3–6 months if symptoms return.

Anal fistula surgery costs vary widely depending on the complexity of the procedure and the healthcare system. In the United States, simple fistulotomy performed as day surgery costs $5,000–$10,000 inclusive of facility, anaesthesia, and surgeon fees. Complex fistula repairs (LIFT, advancement flap, VAAFT) cost $10,000–$20,000, reflecting longer operative time, specialised equipment, and overnight stay. Crohn's perianal fistula management requiring infliximab biologic therapy adds $15,000–$25,000 annually for the infusion cost alone in the USA.

In India, anal fistula surgery at specialist colorectal units (Apollo, Fortis, AIIMS, Manipal, Tata Memorial-linked centres) costs $600–$2,000 for simple fistulotomy and $1,500–$4,000 for complex LIFT or VAAFT procedures — representing a saving of 80–90% versus US prices. VAAFT equipment (Karl Storz fistuloscope) is available at several major Indian centres. Thailand charges $1,500–$4,500 for complex fistula repairs; Singapore SGD 5,000–15,000; Turkey €1,200–€4,000. Generic infliximab (biosimilar — Infimab, CT-P13) is substantially cheaper in India (₹8,000–15,000 per infusion versus $6,000–10,000 in the USA), making India particularly attractive for Crohn's-associated fistula patients requiring combined biologic + surgical management.

For patients with complex fistulae requiring multiple staged procedures, the total treatment episode — including surgical episodes, anoscopy/proctoscopy, MRI, biological therapy, and wound care — should be factored into cost planning for medical tourism.

Platelet-rich plasma (PRP) injection into the fistula track has been evaluated in small studies as a biological sealant with regenerative properties, achieving closure in 40–70% in early series. Further RCT evidence is needed before widespread adoption. Adipose-derived stromal vascular fraction (SVF) and mesenchymal stem cell injection (Alofisel — darvadstrocel) into complex perianal Crohn's fistulae achieved combined remission in 50.3% versus 34% with placebo at week 24 in the ADMIRE-CD phase III trial. Darvadstrocel (Alofisel) received EMA approval in 2018 for complex Crohn's perianal fistulae — the first cell therapy approved for this indication.

Laser ablation of the fistula track (FiLaC — Fistula Laser Closure): A 360-degree laser probe is introduced into the fistula track, ablating the track epithelium. Success rates of 40–64% in published series — similar to fibrin glue or plug, with minimal sphincter risk. The device (Biolitec, Germany) is available at selected European and Asian centres. Radiofrequency ablation of the track: Similar concept using heat energy from radiofrequency current, with preliminary success rates of 50–70% in pilot studies.

For Crohn's disease, newer biologics — vedolizumab (gut-selective anti-α4β7 integrin), ustekinumab (anti-IL-12/23), and risankizumab (anti-IL-23) — are being investigated for perianal Crohn's fistulae in RCTs following their efficacy in luminal Crohn's disease, potentially expanding pharmacological options for the most challenging patients.